Furthermore, tumors with high tumor mutational burden (TMB) or microsatellite instability-high (MSI-H) status indicate increased neoantigen loads, often translating into better responses to PD-1/PD-L1 inhibitors (105). This evidence concerns the gene CD274 and neoplasm.